Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) is a biopharmaceutical company. Following its acquisition of Azora Therapeutics, Adial’s pipeline now includes AT177, a novel, colon-targeted aryl hydrocarbon receptor (AhR) agonist in development for ulcerative colitis, as well as AD04, a genetically targeted serotonin-3 receptor antagonist being advanced through a new Phase 3 clinical trial program for the treatment of Alcohol Use Disorder in patients with certain target genotypes.